{
    "nct_id": "NCT05015374",
    "title": "Effect of Astaxanthin on the Patients With Alzheimer Disease",
    "status": "COMPLETED",
    "last_update_time": "2024-09-25",
    "description_brief": "This study adapts a randomized, double-blind, placebo-controlled trial, to exam the possible benefit of Astaxanthin on Alzheimer disease. The enrolled Alzheimer patients will take Astaxanthin or placebo for 1 year. We will follow up Mini-Mental State Examination, Cognitive Ability Screening Instrument, Clinical Dementia Rating, and Neuropsychiatric Inventory at the end of the study.",
    "description_detailed": "This study aims to examine the benefit of Astaxanthin as adjuvant therapy for Alzheimer's disease.",
    "phase": [
        "NA"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "cognitive enhancer",
    "drug": [
        "Astaxanthin"
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: The intervention is astaxanthin, a dietary carotenoid with potent antioxidant/anti-inflammatory and putative neuroprotective properties, i.e., a small molecule nutraceutical rather than a biologic. \ue200cite\ue202turn0search4\ue201",
        "Act: The trial tests astaxanthin versus placebo for 1 year with cognitive endpoints (MMSE, CASI, CDR) and neuropsychiatric inventory\u2014indicating the primary intent is to improve/maintain cognition rather than to deliver a targeted anti-amyloid or anti-tau biologic. Therefore it fits the 'cognitive enhancer' category. \ue200cite\ue202turn0search1\ue202turn0search5\ue201",
        "Supporting nuance: Preclinical/animal studies report astaxanthin can reduce oxidative stress, neuroinflammation and in some models lower amyloid and tau markers, suggesting possible disease-modifying potential in animals; but the human trials and the described protocol aim at cognitive/neuropsychiatric outcomes rather than a pathway-specific anti-amyloid/tau mechanism. This creates some ambiguity, but classification should follow the trial's measured outcomes and mechanism (antioxidant/neuroprotective) \u2014 hence 'cognitive enhancer'. \ue200cite\ue202turn0search2\ue202turn0search3\ue201",
        "Reflect: Conclusion checked\u2014astaxanthin is a small-molecule carotenoid supplement tested for cognitive benefit in AD patients; it is not a monoclonal antibody or vaccine (so not a disease-targeted biologic), nor is it described as a small-molecule drug designed to inhibit a specific AD pathological enzyme/pathway (so not clearly a disease-targeted small molecule). The best-fit category is 'cognitive enhancer'. \ue200cite\ue202turn0search4\ue202turn0search1\ue201"
    ],
    "agent_type": "G) Oxidative Stress",
    "explanation_agent": [
        "Reason: The intervention is astaxanthin, a small\u2011molecule xanthophyll carotenoid with well\u2011described antioxidant (and secondary anti\u2011inflammatory / neuroprotective) actions \u2014 the mechanism relevant to Alzheimer's is reduction of oxidative stress and related pathways. \ue200cite\ue202turn1search4\ue202turn1search0\ue201",
        "Act: The described trial (Effect of Astaxanthin on the Patients With Alzheimer Disease, NCT05015374) tests astaxanthin versus placebo with cognitive and neuropsychiatric endpoints over 1 year \u2014 the protocol and drug identity indicate a nutraceutical antioxidant approach rather than an amyloid\u2011 or tau\u2011targeted biologic/small\u2011molecule enzyme inhibitor, so the most specific CADRO match is oxidative stress. \ue200cite\ue202turn0search1\ue202turn0search5\ue201",
        "Reflect: Reviews and preclinical studies also report anti\u2011inflammatory, anti\u2011apoptotic, synaptic/neurogenic effects and occasional reductions in amyloid/tau markers in animal models; these secondary mechanisms create some overlap with CADRO categories F (Inflammation) and M (Synaptic plasticity/Neuroprotection), but astaxanthin\u2019s primary, well\u2011characterized bioactivity is antioxidant/anti\u2011oxidative\u2011stress \u2014 therefore G) Oxidative Stress is the best single\u2011category assignment. \ue200cite\ue202turn1search3\ue202turn0search2\ue201",
        "Web search results (key sources used): 1) Trial record for 'Effect of Astaxanthin on the Patients With Alzheimer Disease' (NCT05015374) \u2014 trial design, endpoints, intervention (astaxanthin vs placebo). \ue200cite\ue202turn0search1\ue202turn0search5\ue201 2) 'Exploring astaxanthin: a comprehensive review on its pharmacokinetics properties and neuroprotective potential' \u2014 describes potent antioxidant, anti\u2011inflammatory and BBB penetration / neuroprotection. \ue200cite\ue202turn1search4\ue201 3) 'Neuroprotective and Neurotrophic Effects of Astaxanthin on the Brain' \u2014 review highlighting antioxidant and anti\u2011inflammatory neuroprotective mechanisms. \ue200cite\ue202turn1search0\ue201 4) 'Dietary Astaxanthin: ... brain aging and adult neurogenesis' \u2014 notes antioxidant and anti\u2011inflammatory actions and effects on neurogenesis pathways. \ue200cite\ue202turn1search2\ue201 5) Preclinical study examples showing reductions in amyloid/tau markers and improvements in AD models (supporting secondary disease\u2011modifying signals in animals). \ue200cite\ue202turn0search2\ue202turn0search6\ue201"
    ]
}